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AbstrAct
Systemic sclerosis (SSc) is an orphan disease 
characterised by autoimmunity, fibrosis of the skin 
and internal organs, and vasculopathy. SSc may be 
associated with high morbidity and mortality. in this 
narrative review we summarise the results of a systematic 
literature research, which was performed as part of 
the european Reference Network on Rare and Complex 
Connective Tissue and Musculoskeletal Diseases 
project, aimed at evaluating existing clinical practice 
guidelines or recommendations. Only in the domains 
‘vascular & Ulcers’ (ie, non-pharmacological approach 
to digital ulcer), ‘PAH’ (ie, screening and treatment), 
‘Treatment’ and ‘Juveniles’ (ie, evaluation of juveniles 
with Raynaud’s phenomenon) evidence-based and 
consensus-based guidelines could be included. Hence 
there is a preponderance of unmet needs in SSc referring 
to the diagnosis and (non-)pharmacological treatment 
of several SSc-specific complications. Patients with SSc 
experience significant uncertainty concerning SSc-related 
taxonomy, management (both pharmacological and non-
pharmacological) and education. Day-to-day impact of the 
disease (loss of self-esteem, fatigue, sexual dysfunction, 
and occupational, nutritional and relational problems) is 
underestimated and needs evaluation.
InTroduCTIon
The European Reference Network (ERN) on 
Rare and Complex Connective Tissue and 
Musculoskeletal Diseases (ReCONNET) has 
as one of its aims to deliver high-quality and 
homogeneous care for the management of rare 
connective tissue diseases (rCTDs) across Euro-
pean borders through the identification and 
development of standard clinical guidelines 
and cost-effective pathways. In order to design 
such pathways, current existing clinical practice 
guidelines, more specifically recommendations 
or consensuses concerning management (ie, 
diagnosis, monitoring and treatment), need to 
be identified.1 One of the rCTDs covered by the 
ERN ReCONNET is systemic sclerosis (SSc), an 
orphan disease characterised by autoimmunity, 
fibrosis of the skin and internal organs, and 
vasculopathy. SSc may be associated with high 
morbidity and mortality.2 3 Due to its hetero-
geneity, it is associated with a high uncertainty 
Key messages 
What is already known about this subject?
 ► There is an unmet need for clinical practice guide-
lines in several domains in managing the systemic 
sclerosis (SSc) patients. A holistic management of 
the SSc patients will be paramount.
What does this study add?
 ► This systematic review reports the state of the art on 
existing clinical guidelines and unmet needs in the 
management of SSc patients.
How might this impact on clinical practice or 
future developments?
 ► The european Reference Network (eRN) on Rare and 
Complex Connective Tissue and Musculoskeletal 
Diseases (ReCONNeT) will preceed to deliver high 
quality and homogeneous care for the management 
of SSc through development of holistic standard 
clinical guidelines.
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for the patient who does not know what complication may 
occur and how to treat it. Aside from this, it is a disease 
which may impact the quality of life.4 5 Also for the physi-
cian SSc is challenging. Due to its rarity, it is a disease which 
is uncommon to non-expert rheumatologists, which may 
lead to late diagnosis of the disease or its complications 
and jeopardisation of optimal management of the patient.6 
Also, a disease-modifying drug which tackles the natural 
evolution of the disease itself is yet to be discovered.
The objective of this paper is to report the state of the 
art on existing clinical practice guidelines and the unmet 
needs concerning the management of SSc, based on an 
indepth systematic literature review.
MeTHods
Identification of existing guidelines
We reviewed all published articles in order to identify 
existing clinical practice guidelines on the diagnosis, 
monitoring and treatment of SSc, according to the 
Institute of Medicine1 2011 definition (clinical practice 
guidelines are statements that include recommendations 
intended to optimise patient care that are informed by 
a systematic review of evidence and an assessment of the 
benefits and harms of alternative care options).
The systematic search was performed by the ERN 
ReCONNET Coordinator team (RT, CAS) based on the 
controlled medical subject heading (MeSH) and Emtree 
terms for ‘systemic sclerosis’, in combination with the 
specification of publication type (see below).
The disease coordinators (DCs) of the ERN-ReCONNET 
for SSc (MM-C, VS) assigned the work on clinical practice 
guidelines to the healthcare providers (HCPs) involved. 
Moreover, in order to implement the list of guidelines 
provided by Medline and Embase search, the group 
also performed a hand search. A first screening among 
papers included in the final list (systematic search+hand 
search) based on the title and abstract selected evidence-
based medicine guidelines. The electronic search was 
supplemented by a call to national societies and ERN 
ReCONNET HCPs to identify existing national guide-
lines, and additionally a complementary hand search to 
identify clinical practice guidelines through reference 
lists of the articles was performed by the DCs as well as by 
the ERN ReCONNET Coordinator team.
A general assessment of the clinical practice guide-
lines was performed following the Advancing Guideline 
Development, Reporting and Evaluation in Healthcare 
(AGREE) II tool checklist, not for formal appraisal but 
only to inform discussion. A discussion group was set for 
the evaluation of the existing clinical practice guidelines 
and to identify the unmet needs.
More specifically the following search strategy was 
followed:
Medline (PubMed)
(“scleroderma, systemic” (MeSH Terms) OR (“scleroderma” 
(All Fields) AND “systemic” (All Fields)) OR “systemic sclero-
derma” (All Fields) OR (“systemic” (All Fields) AND “sclerosis” 
(All Fields)) OR “systemic sclerosis” (All Fields)) AND (“Prac-
tice Guideline” (Publication Type) OR “Practice Guidelines As 
Topic” (MeSH Terms) OR Practice Guideline (Publication Type) 
OR “Practice Guideline” (Text Word) OR “Practice Guidelines” 
(Text Word) OR “Guideline” (Publication Type) OR “Guide-
lines As Topic” (MeSH Terms) OR Guideline (Publication Type) 
OR “Guideline” (Text Word) OR “Guidelines” (Text Word) OR 
“Consensus Development Conference” (Publication Type) OR 
“Consensus Development Conferences As Topic” (MeSH Terms) 
OR “Consensus” (MeSH Terms) OR “Consensus” (Text Word) 
OR “Recommendation” (Text Word) OR “Recommendations” 
(Text Word) OR “Best Practice” (Text Word) OR “Best Practices” 
(Text Word)).
embase
(‘systemic sclerosis’/exp OR ‘generalised scleroderma’ OR ‘gener-
alized scleroderma’ OR ‘progressive scleroderma’ OR ‘progressive 
sclerodermia’ OR ‘progressive sclerosis, systemic’ OR ‘progres-
sive systemic sclerosis’ OR ‘scleroderma, generalised’ OR ‘scle-
roderma, generalized’ OR ‘scleroderma, progressive’ OR ‘sclero-
derma, systemic’ OR ‘sclerosis, progressive systemic’ OR ‘sclerosis, 
systemic’ OR ‘sclerosis, systemic progressive’ OR ‘systemic progres-
sive sclerosis’ OR ‘systemic scleroderma’ OR ‘systemic sclerosis’ 
OR ‘systemic sclerosis, progressive’) AND (‘practice guideline’/
exp OR ‘practice guideline’ OR ‘practice guidelines’/exp OR 
‘practice guidelines’ OR ‘clinical practice guideline’/exp OR 
‘clinical practice guideline’ OR ‘clinical practice guidelines’/
exp OR ‘clinical practice guidelines’ OR ‘clinical practice guide-
lines as topic’/exp OR ‘clinical practice guidelines as topic’ OR 
‘guideline’/exp OR ‘guideline’ OR ‘guidelines’/exp OR ‘guide-
lines’ OR ‘guidelines as topic’/exp OR ‘guidelines as topic’ OR 
‘consensus development’/exp OR ‘consensus development’ OR 
‘consensus development conference’/exp OR ‘consensus develop-
ment conference’ OR ‘consensus development conferences’/exp 
OR ‘consensus development conferences’ OR ‘consensus devel-
opment conferences as topic’/exp OR ‘consensus development 
conferences as topic’ OR ‘consensus’/exp OR ‘consensus’ OR 
‘recommendation’ OR ‘recommendations’) AND (embase)/lim 
NOT (medline)/lim.
The list with identified references was independently 
screened at the title and abstract levels by two SSc-DCs 
and the ERN ReCONNET Coordinator team. Refer-
ences were selected for inclusion based on predefined 
eligibility criteria. More specifically, evidence-based 
medicine guidelines, recommendations or consensuses 
documenting the diagnosis, monitoring or treatment of 
SSc (according to the 1980 American College of Rheu-
matology (ACR) or the 2013 ACR/European League 
Against Rheumatism (EULAR) criteria) were considered 
eligible.1 7 8 Subsequently, these references were classified 
according to SSc complications/disease manifestations, 
more specifically in the following domains, as decided by 
the SSc-DC: ‘Patients’, ‘Heart’, ‘Malignancy’, ‘Vascular 
& Ulcers’, ‘Gastro-intestinal (GI)’, ‘Renal’, ‘Intersti-
tial Lung Disease (ILD)’, ‘Pulmonary Arterial Hyper-
tension (PAH)’, ‘Diagnosis’, ‘Contribution of HCPs’, 
‘Treatment’, ‘Hematopoietic Stem Cell Transplantation 
(HSCT)’, ‘Clinical Trials’ and ‘Juvenile’.
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Table 1 Clinical practice guidelines in systemic sclerosis: 
where do we stand?
Domain (n) Author and year
Level of 
evidence10
Patients (0) No clinical practice guidelines were 
included.
Heart (3) Avouac et al, 201418 S2
Bissell et al, 201719 S2
Mavrogeni et al, 201620 S2
Malignancy (1) Lazzaroni et al, 201721 S2
Vascular and ulcers (6) Baron et al, 201422 S2
Fujimoto et al, 201623 S2
Hughes et al, 201524 S2
Pistorius et al, 201225 S1
Maverakis et al, 201426 S2
Cutolo et al, 201727 S1
Gastrointestinal (3) Alantar et al, 201128 S2
Baron et al, 201029 S1
Hansi et al, 201430 S2
Renal (1) Lynch et al, 201631 S1
Interstitial lung disease 
(0)
No clinical practice guidelines were 
included.
Pulmonary arterial 
hypertension (2)
Galiè et al, 201632 S3
Khanna et al, 201333 S3
Diagnosis (1) Knobler et al, 201734 S1
Contribution of 
healthcare providers (0)
No clinical practice guidelines were 
included.
Treatment (5) Kowal-Bielecka et al, 
201735
S3
Denton et al, 20166 S2
Sampaio-Barros et al, 
201336
S2
Distler et al, 201137 S2
Knobler et al, 201438 S2
Haematopoietic stem 
cell transplantation (3)
Rodrigues et al, 201339 S2
Saccardi et al, 200440 S2
Farge et al, 201741 S2
Clinical trials (2) Khanna et al, 201542 S3
Khanna et al, 201043 S1
Juvenile (1) Pain et al, 201644 S3
Level of evidence: Amendment of the ‘S-class’ classification 
is used to describe the degree of systematic development of 
guidelines and thus to identify their level of evidence, by the 
German Association of the Scientific Medical Societies Guidance 
Manual and Rules for Guideline Development:10 category S3: 
evidence-based and consensus-based guideline, based on a 
representative committee, systematic review andsynthesis of 
evidence (highest level of evidence); category S2: evidence-based 
or consensus-based guideline, based on either a systematic review 
and synthesis of evidence or a representative committee; category 
S1: recommendations by expert groups, based on consensus 
development in an informal procedure (lowest level of evidence).
For preparing the state of the art of the retained full 
texts, the SSc-DCs sent two invitational emails to involved 
HCPs who had expressed their interest to participate in 
the guideline review. Full texts were further excluded 
when not meeting the inclusion criteria, as described 
above, in order to retain clinical practice guidelines (see 
table 1).
evaluation of existing clinical practice guidelines
The first screening and informal assessment of the 
methodological ‘overall’ quality of each clinical prac-
tice guideline were guided by the AGREE II instru-
ment.9 A general assessment of the state of the art on 
clinical practice guidelines and unmet needs identi-
fication was performed by the SSc-DCs. Additionally, 
the levels of evidence were assessed by the SSc Junior 
Coordinator team (AmV, VS) using the German Asso-
ciation of the Scientific Medical Societies Guidance 
Manual and Rules for Guideline Development (see 
table 1).10
Additionally, patients’ unmet needs of the Systemic 
Sclerosis/Scleroderma European community have been 
formulated by the ERN ReCONNET European Patient 
Advocacy Group (ePAG), that is, IG that had carefully 
collected the voices and the points of view of the whole 
European community and had found evidence in the 
literature.11–17 Subsequently a synthesis of these has 
been described by the SSc-ePAG and SSc-DCs (see the 
‘Patients’ unmet needs’ section).
sTaTe of THe arT on ClInICal praCTICe guIdelInes
Identification of existing guidelines
The systematic search in PubMed and Embase identi-
fied 893 references; the call to societies identified Dutch 
guidelines, the call to ERN-related HCPs identified no 
references and the hand search identified one addi-
tional reference. Of note, the Dutch guidelines were not 
included in the final list to be screened at the title and 
abstract levels since they had not yet been published in 
English peer-reviewed journals. Of the final list (n=894), 
28 clinical practice guidelines were retained (see 
figure 1).6 18–44
evaluation of existing guidelines
Overall comments of the appraisers were mostly referring 
to the non-systematic review aspect of the recommenda-
tions. Evaluation of the levels of evidence showed that 
only five guidelines were classified as strong evidence-
based and consensus-based guidelines built on a repre-
sentative committee, systematic review and synthesis of 
evidence, and will be stipulated as such below.32 33 35 42 44
Patients
Guidelines in the domain of patients are non-existent. 
Nevertheless, based on exhaustive patient input (IG), 
guidelines covering the unmet needs of the patients 
are highly warranted (see the ‘Patients’ unmet needs’ 
section).
Heart
Three references were retained in the domain ‘Heart’.
First, Avouac et al18 proposed interim recommenda-
tions to refer patients with SSc for performing right heart 
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Figure 1 Flow chart of the screening process. ERN ReCONNET, European Reference Network Rare and Complex Connective 
Tissue and Musculoskeletal Diseases; DC, disease coordinators; HCP, healthcare providers; HSCT, haematopoietic stem 
cell transplantation; ILD, interstitial lung disease; JC, Junior Coordinator; PAH, pulmonary arterial hypertension; SC, Senior 
Coordinator; SSc, systemic sclerosis.
catheterisation (RHC) for detecting PAH in SSc when 
suspected. Of note, these have now been encompassed 
in the highest level of evidence guideline, more specif-
ically the 2015 European Society for Cardiology/Euro-
pean Respiratory Society (ESC/ESR) evidence-based 
and consensus-based guideline for the diagnosis and 
treatment of pulmonary hypertension (see the ‘Pulmo-
nary arterial hypertension’ section). Second, Bissell et al19 
presented, on behalf of the UK Scleroderma Study Group 
(UKSSG), a consensus best practice pathway for the 
management of cardiac disease, with a focus on primary 
heart disease in SSc. More specifically, approaches for 
early detection, standard pharmacological and device 
therapies have been put forward. Additionally, besides 
the recommendation for a multidisciplinary approach, 
a future research agenda has also been formulated in 
response to the relative lack of understanding of the 
natural history of primary cardiac disease. Third, Mavro-
geni et al20 described possible recommendations for the 
use of cardiac magnetic resonance in rare connective 
tissue diseases (rCTDs) and in between others, also in 
SSc.
Malignancy
One reference was retained in the domain ‘Malignancy’. 
More specifically, Lazzaroni et al21 described possible 
recommendations for the screening for malignancies in 
patients with SSc with anti-RNA polymerase III. These 
recommendations were based on a Delphi exercise which 
was performed with the European League Against Rheu-
matism Scleroderma Trials and Research (EUSTAR) 
experts.
vascular and ulcers
Six references were included in the domain ‘Vascular & 
Ulcers’.
First, the North American Working Group regarding 
the classification of digital ulcers (DUs) in SSc developed 
a consensus for the classification of DUs, which after 
training of rheumatologists with SSc expertise could be 
used with fair reliability to classify DUs and to measure 
ulcer area.22 45
Second, Fujimoto et al23 described, on behalf of the 
Wound/Burn Guidelines Committee of the Japanese 
Dermatological Association, recommendations for the 
management of skin ulcers associated with CTD/vascu-
litis. In this way, an algorithm for SSc-related ulcers was 
proposed, as well as a reply to frequently asked ques-
tions in the care of SSc-related ulcers. Third, Hughes 
et al24 published, on behalf of the UKSSG, a best prac-
tice consensus recommendation for digital vasculopathy 
intended as a reference tool to inform management. In 
this way algorithms for the management of Raynaud’s 
phenomenon (RP), DUs and critical digital ischaemia in 
patients with SSc have been proposed.
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Fourth, in the recommendations by expert groups 
of Pistorius et al,25 on behalf of the French Society of 
Vascular Medicine and the French Society for Microcir-
culation, clinical guidelines (more specifically clinical 
examination, nailfold capillaroscopy and antinuclear 
antibodies) as a work-up of patients with RP were defined. 
Besides this, a consensus-based recommendation was 
recently developed to diagnose RP and primary RP.26 
Unfortunately, high evidence level guidelines based on 
the combination of a representative committee, system-
atic review and synthesis of evidence are lacking on the 
topic of primary versus secondary RP.
Interestingly, points to consider for clinical trials in SSc-as-
sociated RP have also been suggested by Cutolo et al.27
Gastrointestinal
Three references were included concerning ‘GI’ recom-
mendations.
Alantar et al28 described, on behalf of a French multi-
disciplinary working group, recommendations for the 
care of oral involvement (prevention of oral and dental 
complications, as well as SSc-tailored dental treatment) 
in patients with SSc.
Baron et al29 published, on behalf of the Canadian 
Scleroderma Research Group, recommendations for the 
screening and management of malnutrition and GI-re-
lated manifestations. Lastly, Hansi et al30 proposed, on 
behalf of the UKSSG, symptom-based algorithms as a 
useful tool and point of reference concerning gastro-oe-
sophageal symptoms, abdominal pain and distention, 
weight loss and nutritional issues, diarrhoea, inconti-
nence and constipation.
Renal
One reference was included as recommendation in the 
domain ‘Renal’. More specifically, Lynch et al,31 on behalf 
of the UKSSG, provided recommendations for the diag-
nosis, including essential and supportive criteria, and 
management of scleroderma renal crisis (SRC).
interstitial lung disease
No clinical practice guideline on ‘Interstitial Lung 
Disease’ as such, but only as part of the recommenda-
tions from the British Society for Rheumatology (BSR)/
British Health Professionals in Rheumatology (BHPR) 
had been retained after the systematic search, stating that 
all SSc cases should be evaluated for lung fibrosis and 
that treatment is to be determined by the extent, severity 
and the likelihood of progression to severe disease.6
Pulmonary arterial hypertension
Two references were included in the domain ‘PAH’.32 33 
Galiè et al32 developed, on behalf of the ESC and ERS, 
evidence-based and consensus-based recommendations 
for the diagnosis and treatment of PAH, which recom-
mend resting transthoracic echocardiography (TTE) as a 
screening test in asymptomatic patients with SSc, followed 
by annual screening with TTE, Diffusing capacity of the 
lung for carbon monoxide (DLCO) and biomarkers. Of 
note, screening using the DETECT algorithm, a two-step 
diagnostic algorithm with clinical, laboratory, lung func-
tional and electrocardiography parameters in step 1 
and TTE in step 2, before mandating RHC to evaluate 
patients with SSc at risk for PAH may be considered to 
screen for PAH in adult patients with SSc with >3 years of 
disease duration and a DLCO <60% predicted. However, 
in an unselected SSc cohort, the performance charac-
teristics of the DETECT algorithm do not outweigh the 
ESC/ERS guidelines.46 Of note, in 2013 similar screening 
recommendations had been recommended in SSc and 
scleroderma spectrum disorders in the evidence-based 
and consensus-based recommendations by Khanna et 
al.33 These latter have now been encompassed by the 
ESC/ESR and DETECT.
Diagnosis
Only one reference was included in the domain ‘Diag-
nosis’, more specifically the recommendations by the 
expert groups of Knobler et al,34 on behalf of the Euro-
pean Dermatology Forum, for the diagnosis and treat-
ment of sclerosing diseases of the skin which encom-
passed SSc. The criteria for early and very early diag-
nosis of SSc, as well as the frequently used 2013 ACR/
EULAR classification criteria, had not been retained as 
an in ‘verum guideline’, but are nevertheless used in the 
management of patients with SSc.8 47 48
Contribution of HCPs
No references were included after title and abstract 
screening in the domain ‘Contribution of HCPs’.
Treatment
Five references were retained in the domain ‘Treatment’.
The updated evidence-based and consensus-based 
EULAR recommendations of Kowal-Bielecka et al35 focus 
specifically on the management of SSc features (RP, 
DU, PAH, skin disease, lung disease, SRC, GI disorders), 
and include data on newer therapeutic modalities and 
mention a research agenda. These recommendations are 
pharmacological, with few guidelines regarding investi-
gations and non-pharmacological treatment.49 Recom-
mendations from the BSR/BHPR are similar to the organ 
manifestations mentioned in the EULAR recommen-
dations and expand on several domains of treatment, 
including general measures, non-pharmacological treat-
ment, cardiac involvement, and calcinosis and musculo-
skeletal features.6 49 Sampaio-Barros et al had described 
previously, on behalf of the Brazilian Society of Rheuma-
tology, recommendations for the management and treat-
ment of SSc, which have been encompassed by the more 
recent EULAR and BSR/BHPR recommendations.6 35 36
Recommendations concerning specific therapies, 
more specifically the role of photopheresis and antitu-
mour necrosis factor in SSc, have been published.37 38 
Of note, these therapies have not been included in the 
recent EULAR or BSR/BHPR guidelines.
 o
n
 7 N
ovem
ber 2018 by guest. Protected by copyright.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2018-000782 on 18 O
ctober 2018. Downloaded from
 
6 Smith v, et al. RMD Open 2018;4:e000782. doi:10.1136/rmdopen-2018-000782
RMD Open
Haematopoietic stem cell transplantation
Three references were retained in the domain ‘HSCT’.
In 2013 Rodrigues et al,39 on behalf of the Brazilian 
Society of Bone Marrow Transplantation, developed 
recommendations on the use of HSCT as a treatment for 
SSc.
Concerning HSCT-related cardiotoxicity, consen-
sus-based guidelines were published in 2004 and 
2017. Saccardi et al40 published a consensus statement 
concerning cardiotoxicity during HSCT in SSc and 
recommendations concerning full cardiological assess-
ment prior to HSCT. In the consensus-based guideline 
of Farge et al,41 on behalf of the European Society for 
Blood and Marrow Transplantation (EBMT) Autoim-
mune Diseases Working Party, more recent recommen-
dations concerning the cardiopulmonary assessment of 
patients with SSc prior to HSCT were developed. The 
latter includes, besides anamnesis and clinical examina-
tion, standard haematological, biological, urinary, immu-
nological, cardiopulmonary and GI investigations and 
additionally selection criteria to use HSCT in SSc.
Clinical trials
Two references were included in the domain ‘Clinical 
trials’ (besides the one already mentioned above in the 
‘Vascular & Ulcers’ section).27 42 43
In the evidence-based and consensus-based guideline 
of Khanna et al,42 22 points to consider based on EULAR 
standards for the design of controlled clinical trials in SSc 
were developed.
In the recommendations by the expert groups of 
Khanna et al,43 preliminary recommendations for the 
design of future SSc-ILD randomised clinical trials were 
proposed.
Of note, a post-hoc search of the SSc-DCs identified 
several recently published ‘points to consider for clin-
ical trials’ in the following areas: ‘Health-Related Quali-
ty-of-Life’, ‘Arthritic Involvement’, ‘GI tract’, ‘Pulmonary 
Hypertension’, ‘Muscle Involvement’, ‘Heart’, ‘Skin 
Ulcers’, ‘Renal’ and ‘Interstitial Lung Disease (ILD)’.50–58 
Of note, Johnson et al59 highlighted in 2015 recent 
advances in research methodology and broadened the 
potential range of design and analytic considerations 
when planning an SSc trial.
Juvenile
One reference was retained in the domain ‘Juvenile’.
In the evidence-based and consensus-based guideline 
of Pain et al,44 on behalf of the Paediatric Rheumatology 
European Society Juvenile Scleroderma Working Group, 
recommendations for the assessment and monitoring of 
RP in children were proposed.
unMeT needs IdenTIfICaTIon
This is the first clinical narrative review investigating 
clinical practice guidelines in the field of SSc. Of all 
the described domains, only in the domains ‘Vascular 
& Ulcers’ (ie, non-pharmacological approach to DU), 
‘PAH’ (ie, screening and treatment), ‘Treatment’ and 
‘Juveniles’ (ie, evaluation of juveniles with RP) evidence-
based and consensus-based guidelines could be included. 
Hence there is a preponderance of unmet needs in SSc.
Clinicians‘ unmet needs
There is a lack of (strong evidence) recommendations 
regarding diagnosis and (non-)pharmacological treat-
ment of several SSc-specific complications. In particular, 
a contribution could be given for ulcers, GI tract 
involvement, renal involvement and management of 
calcinosis. Incentives in this field are ongoing.60 In this 
way, non-exhaustively, the World Scleroderma Founda-
tion has recently proposed preliminary evidence-based 
and consensus-based guidelines on how to define DU.61 
Nevertheless, more intensive research should be done 
to provide the SSc community with high evidence-
based and consensus-based guidelines to address any 
facet of this heterogeneous disease, which could then 
be dispersed to policy makers at the (inter-)national 
level as well as to HCP and physicians dealing with this 
disease.
Of note, the lack of strong evidence recommenda-
tions (ie, based on a systematic review and a represen-
tative internationally composed committee and at least 
one patient representative) extrapolates to cross-disci-
pline therapies such as to the use of HSCT in patients 
with SSc.62 In this way detailed recommendations on 
the main clinical features of patients with SSc are an 
important unmet need to be addressed in the future 
in connection with other institutional entities such as 
the EBMT, EULAR and EUSTAR. Also, clinical prac-
tice guidelines stipulating the role of steroids in SSc are 
highly warranted.63
At present, evidence-based and consensus-based guide-
lines for very early and early diagnosis of SSc still remain 
an unmet need, although the criteria for (very) early 
diagnosis are present in literature.47 48 In this area, the 
contribution of SSc-ERN could be to raise awareness 
among physicians on the problem and foster the early 
referral of patients to tertiary centres. Moreover, the 
problem to be addressed by SSc-ERN is the use of clas-
sification criteria to diagnose SSc. This highlights the 
absence of diagnostic criteria that are useful in practice. 
It is also to be noted that the dispersion (teaching and 
interpretation) of nailfold videocapillaroscopy (NVC) in 
a standardised way to early detect patients with RP who 
will develop SSc may be steered by both the ERN and the 
EULAR Study Group on Microcirculation in Rheumatic 
Diseases.64–66 Of note, NVC has been introduced in the 
ACR/EULAR criteria for SSc.8
From the methodological point of view, it is interesting 
to notice that the ERN ReCONNET may foster awareness 
of standardisation of SSc-specific investigational tech-
niques (eg, antibody assays for SSc-specific antibodies). 
This may help to definitively reach an agreement on the 
standardised evaluation of patients with SSc.
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patients’ unmet needs
Patients with SSc experience significant uncertainty 
concerning SSc-related taxonomy, management (both 
pharmacological and non-pharmacological) due to 
lack of (inter-)national harmonisation and standardisa-
tion and due to non-existence of overarching evidence-
based and consensus-based guidelines for holistic SSc 
management. Access to uniform information, including 
knowledgeable HCPs, and management of difficult social 
interactions and negative emotions are key challenges.11 
Patient education programmes should be promoted.
Besides these, patients with SSc incur considerable 
costs (eg, non-reimbursement of certain therapies) and 
experience substantial deterioration in health-related 
quality of life (HRQoL).12 13 Additionally, no specific 
recommendations are at hand regarding non-pharma-
cological interventions (eg, behavioural/psychological, 
educational, physical/occupational therapy) to improve 
HRQoL. However, incentives like the ‘Scleroderma 
Patient centered Intervention Network’, which aims to 
develop, test and disseminate a set of accessible interven-
tions designed to complement standard care to improve 
HRQoL, are encouraging.14
Importantly, patient participation in patient-reported 
outcome measures, meant to provide insight into the 
patient condition which is not fully captured by physi-
cian-derived assessment tools, has been non-prevalent 
even though this is paramount to ensure adequate 
capturing of those experiences most important to our 
patients.15
Last but not least, day-to-day impact of the disease (loss 
of self-esteem, fatigue, sexual dysfunction, and occupa-
tional, nutritional and relational problems) is underes-
timated.16 17
ConClusIon
This indepth systematic literature review identified 28 
clinical practice guidelines concerning the manage-
ment of SSc. More specifically, there is an availability 
of evidence-based and consensus-based guidelines for 
screening of SSc-related PAH, treatment and points to 
consider in clinical trials in SSc, which are updated on 
a regular basis by the SSc community. Furthermore, 
gaps have been identified concerning patients’ needs, 
the role of HCPs, (very) early diagnosis of SSc, several 
specific organ involvements and the use of HSCT in SSc. 
Possible roles of the ERN ReCONNET could be to step 
forward to deal with patients’ unmet needs, to deal with 
the heterogeneity that exists in patient care throughout 
countries, to clearly identify at the European level the 
role of HCPs in the management of patients with SSc, 
and to step forward to the unmet need of (very) early 
diagnosis of the disease as well as its organ involve-
ment, complications and management of complications, 
leading to a standardised, uniform holistic management 
of SSc.
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